BP put out an upgrade to their SP target dated 22nd March
wee snip
"Elixinol has previously stated its intention to pursue national retail deals. There is room for multiple brands within each retailer, indeed, there is no indication from the CVS/Curaleaf announcement of exclusivity on behalf of either party. No changes to earnings. The forecast for FY20 includes a modest allowance for revenues from a national retail deal. Price target is raised to $5.30 (previously $3.39) in anticipation of a significant transaction with one or more national accounts."
Ann: Investor Update March/April 2019, page-25
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.002(33.3%) |
Mkt cap ! $6.605M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $2.103K | 475.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 7670493 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 924824 | 4 |
View Market Depth
| Last trade - 14.04pm 29/11/2024 (20 minute delay) ? |
| EXL (ASX) Chart |
